Reversine inhibits Colon Carcinoma Cell Migration by Targeting JNK1

Research output: Contribution to journalJournal article – Annual report year: 2018Researchpeer-review

Standard

Reversine inhibits Colon Carcinoma Cell Migration by Targeting JNK1. / Jemaa, Mohamed; Abassi, Yasmin; Kifagi, Chamseddine; Fezai, Myriam; Daams, Renee; Lang, Florian; Massoumi, Ramin.

In: Scientific Reports, Vol. 8, No. 1, 11821, 2018.

Research output: Contribution to journalJournal article – Annual report year: 2018Researchpeer-review

Harvard

Jemaa, M, Abassi, Y, Kifagi, C, Fezai, M, Daams, R, Lang, F & Massoumi, R 2018, 'Reversine inhibits Colon Carcinoma Cell Migration by Targeting JNK1' Scientific Reports, vol. 8, no. 1, 11821. https://doi.org/10.1038/s41598-018-30251-w

APA

Jemaa, M., Abassi, Y., Kifagi, C., Fezai, M., Daams, R., Lang, F., & Massoumi, R. (2018). Reversine inhibits Colon Carcinoma Cell Migration by Targeting JNK1. Scientific Reports, 8(1), [11821]. https://doi.org/10.1038/s41598-018-30251-w

CBE

MLA

Vancouver

Author

Jemaa, Mohamed ; Abassi, Yasmin ; Kifagi, Chamseddine ; Fezai, Myriam ; Daams, Renee ; Lang, Florian ; Massoumi, Ramin. / Reversine inhibits Colon Carcinoma Cell Migration by Targeting JNK1. In: Scientific Reports. 2018 ; Vol. 8, No. 1.

Bibtex

@article{a0c70ad5ce924cb6bae2ae5eca4e2e9c,
title = "Reversine inhibits Colon Carcinoma Cell Migration by Targeting JNK1",
abstract = "Colorectal cancer is one of the most commonly diagnosed cancers and the third most common cause of cancer-related death. Metastasis is the leading reason for the resultant mortality of these patients. Accordingly, development and characterization of novel anti-cancer drugs limiting colorectal tumor cell dissemination and metastasis are needed. In this study, we found that the small molecule Reversine reduces the migration potential of human colon carcinoma cells in vitro. A coupled kinase assay with bio-informatics approach identified the c-Jun N-terminal kinase (JNK) cascade as the main pathway inhibited by Reversine. Knockdown experiments and pharmacological inhibition identified JNK1 but not JNK2, as a downstream effector target in cancer cell migration. Xenograft experiments confirm the effect of JNK inhibition in the metastatic potential of colon cancer cells. These results highlight the impact of individual JNK isoforms in cancer cell metastasis and propose Reversine as a novel anti-cancer molecule for treatment of colon cancer patients.",
author = "Mohamed Jemaa and Yasmin Abassi and Chamseddine Kifagi and Myriam Fezai and Renee Daams and Florian Lang and Ramin Massoumi",
year = "2018",
doi = "10.1038/s41598-018-30251-w",
language = "English",
volume = "8",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

RIS

TY - JOUR

T1 - Reversine inhibits Colon Carcinoma Cell Migration by Targeting JNK1

AU - Jemaa, Mohamed

AU - Abassi, Yasmin

AU - Kifagi, Chamseddine

AU - Fezai, Myriam

AU - Daams, Renee

AU - Lang, Florian

AU - Massoumi, Ramin

PY - 2018

Y1 - 2018

N2 - Colorectal cancer is one of the most commonly diagnosed cancers and the third most common cause of cancer-related death. Metastasis is the leading reason for the resultant mortality of these patients. Accordingly, development and characterization of novel anti-cancer drugs limiting colorectal tumor cell dissemination and metastasis are needed. In this study, we found that the small molecule Reversine reduces the migration potential of human colon carcinoma cells in vitro. A coupled kinase assay with bio-informatics approach identified the c-Jun N-terminal kinase (JNK) cascade as the main pathway inhibited by Reversine. Knockdown experiments and pharmacological inhibition identified JNK1 but not JNK2, as a downstream effector target in cancer cell migration. Xenograft experiments confirm the effect of JNK inhibition in the metastatic potential of colon cancer cells. These results highlight the impact of individual JNK isoforms in cancer cell metastasis and propose Reversine as a novel anti-cancer molecule for treatment of colon cancer patients.

AB - Colorectal cancer is one of the most commonly diagnosed cancers and the third most common cause of cancer-related death. Metastasis is the leading reason for the resultant mortality of these patients. Accordingly, development and characterization of novel anti-cancer drugs limiting colorectal tumor cell dissemination and metastasis are needed. In this study, we found that the small molecule Reversine reduces the migration potential of human colon carcinoma cells in vitro. A coupled kinase assay with bio-informatics approach identified the c-Jun N-terminal kinase (JNK) cascade as the main pathway inhibited by Reversine. Knockdown experiments and pharmacological inhibition identified JNK1 but not JNK2, as a downstream effector target in cancer cell migration. Xenograft experiments confirm the effect of JNK inhibition in the metastatic potential of colon cancer cells. These results highlight the impact of individual JNK isoforms in cancer cell metastasis and propose Reversine as a novel anti-cancer molecule for treatment of colon cancer patients.

U2 - 10.1038/s41598-018-30251-w

DO - 10.1038/s41598-018-30251-w

M3 - Journal article

VL - 8

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 11821

ER -